Related Experiment Videos
Clinical benefits of thrombolytic therapy in acute myocardial infarction
1Department of Cardiology, Washington University School of Medicine, St. Louis, Missouri 63110.
Insights
Pharmacological fibrinolysis effectively restores coronary artery blood flow in myocardial infarction patients, significantly improving survival and heart function. Early treatment offers sustained benefits, making it a conventional therapy despite potential bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) requires prompt intervention to restore blood flow.
- Pharmacologically induced fibrinolysis is a key treatment strategy for evolving myocardial infarction.
Purpose of the Study:
- To evaluate the efficacy and safety of fibrinolysis in patients with evolving myocardial infarction.
- To determine the long-term benefits of reperfusion therapy.
Main Methods:
- Review of controlled studies on pharmacologically induced fibrinolysis.
- Analysis of patient subgroups to identify potential contraindications.
- Assessment of risks, including bleeding hazards, associated with fibrinolytic agents.
Main Results:
- Fibrinolysis consistently improves left ventricular function and survival rates.
- Restoration of myocardial blood flow is directly linked to patient benefit.
- Early and sustained coronary artery patency maximizes therapeutic effects.
- Benefits persist for at least 1 year post-treatment, irrespective of mechanical revascularization.
- No specific patient subgroup should be routinely excluded from thrombolysis.
Conclusions:
- Thrombolysis is a safe and effective conventional therapy for acute myocardial infarction.
- Careful patient selection and monitoring are essential due to potential bleeding risks.
- Early reperfusion therapy offers significant and sustained survival benefits.
Abstract:
The value of coronary artery reperfusion resulting from pharmacologically induced fibrinolysis in patients with evolving myocardial infarction has been rigorously evaluated. Improved left ventricular function and even more impressive improvements in survival rates have been demonstrated consistently in controlled studies. Benefit is related to the restoration of myocardial blood flow. Maximal benefit is achieved with early and sustained restoration of coronary artery patency. Benefits observed during initial hospitalization are sustained for at least 1 year in the majority of patients, even without subsequent mechanical revascularization. To date, analysis of subgroups has not identified a population of patients with evolving infarction that should routinely be excluded from consideration for thrombolysis. As with many potent pharmacologic agents, activators of the fibrinolytic system are associated with a degree of risk whenever they are administered to a patient. Therefore, patients must be assessed carefully prior to initiating treatment, especially for potential bleeding hazards, and appropriate follow-up evaluation and concomitant therapy needs to be planned. However, given the overwhelming body of data now available regarding its benefits and relative safety, thrombolysis should be considered as conventional therapy for patients with acute evolving myocardial infarction (AMI).